{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:10:10Z","timestamp":1792275010671,"version":"4.4.0"},"reference-count":37,"publisher":"Massachusetts Medical Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2014,2,20]]},"DOI":"10.1056\/nejmoa1308345","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T17:52:50Z","timestamp":1392832370000},"page":"709-722","source":"Crossref","is-referenced-by-count":2354,"title":["Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma"],"prefix":"10.1056","volume":"370","author":[{"given":"Olivier L.","family":"Chinot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Saran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine F.","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khe","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Cernea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba A.","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"r001","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-492-0_14"},{"key":"r003","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2006-012"},{"key":"r004","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-5-2-89"},{"key":"r005","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.036186"},{"key":"r006","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0565-x"},{"key":"r007","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2001.19.20.4037","volume":"19","author":"Klein M","year":"2001","journal-title":"J Clin Oncol"},{"key":"r008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"r010","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq187"},{"key":"r011","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-200050453"},{"key":"r012","doi-asserted-by":"publisher","DOI":"10.1038\/359845a0"},{"key":"r013","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116165"},{"key":"r014","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"r015","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0007-3"},{"key":"r016","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0272"},{"key":"r017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2440"},{"key":"r018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"r019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"r020","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.10.043"},{"key":"r021","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2729"},{"key":"r022","doi-asserted-by":"publisher","DOI":"10.3171\/2011.9.JNS11656"},{"key":"r023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5963"},{"key":"r025","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-013-0347-2"},{"key":"r026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"r027","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"r028","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435979"},{"key":"r029","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.01.012"},{"key":"r031","doi-asserted-by":"publisher","DOI":"10.2307\/2336502"},{"key":"r032","doi-asserted-by":"crossref","unstructured":"Henriksson R, Bottomley A, Mason W, et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Presented at the 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, May 31\u2013June 4, 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.2005"},{"key":"r033","doi-asserted-by":"publisher","unstructured":"Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. Presented at the 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, May 31\u2013June 4, 2013.","DOI":"10.1200\/jco.2013.31.18_suppl.lba2009"},{"key":"r034","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-008"},{"key":"r035","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70125-6"},{"key":"r036","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8163"},{"key":"r037","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573"},{"key":"r038","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1200\/JCO.2000.18.7.1481","volume":"18","author":"Osoba D","year":"2000","journal-title":"J Clin Oncol"},{"key":"r039","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008382516636"},{"key":"r040","doi-asserted-by":"crossref","unstructured":"Armstrong TS, Won M, Wefel JS, et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Presented at the 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, May 31\u2013June 4, 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.2003"},{"key":"r041","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1170-y"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1308345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T10:50:11Z","timestamp":1597488611000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1308345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,2,20]]}},"alternative-id":["10.1056\/NEJMoa1308345"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa1308345","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718283108.793491447","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718283108.793491574","asserted-by":"object"}]},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}